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Background: Achromobacter xylosoxidans is an emerging pathogen in cystic ﬁbrosis (CF) patients recognised as causal agent of inﬂammation.
The prevalence of infection or colonisation is variable among CF centres. We report here the ﬁrst epidemiological data about A. xylosoxidans in a
French CF centre: Dijon, Burgundy.
Methods: All isolates recovered from the patients afﬁliated with our centre in 2010 since their ﬁrst visit were included. Antimicrobial susceptibility
was determined by disk diffusion method and E-test. Molecular epidemiology was performed by Pulsed Field Gel Electrophoresis (PFGE) and
compared with repetitive sequence-based PCR (rep-PCR, DiversiLab®). We also sequenced the constitutive bla-oxa-114 gene.
Results: Out of 120 patients, 21 (17.5%) had at least one positive culture with A. xylosoxidans since they started to receive routine care in our CF
centre (447 isolates). Median age at ﬁrst positive culture was 16 years (range 3–34 years). Most patients were colonised by their own strain, cross-
contamination was very rare. We observed two cases of intra-family spread. DiversiLab® is a useful tool as efﬁcient as PFGE to compare isolates
recovered simultaneously from different patients when an outbreak is suspected. However, PFGE remains the reference method for long-term
survey of chronically colonised patients. We detected new OXA-114 variants and the new oxacillinase OXA-243 (88% amino acid identity with
OXA-114). Acquired resistance to ciproﬂoxacin, ceftazidime and carbapenems was frequent. In 2010, 7 patients harboured strains resistant to
ceftazidime, 6 patients strains with decreased susceptibility to carbapenems (especially meropenem) and 12 patients strains resistant to
ciproﬂoxacin.
Conclusions: In our centre, the high prevalence of colonisation is not due to cross-contamination. Our main concern is the high rate of
antimicrobial resistance.
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Achromobacter xylosoxidans; Cystic ﬁbrosis; Genotyping; DiversiLab; OXA-114; OXA-243; Resistance1. Introduction
Methicillin-susceptible Staphylococcus aureus, Haemophilus
influenzae and Pseudomonas aeruginosa remain the most
common pathogens isolated during airway infection in cystic
fibrosis (CF) patients [1]. Nevertheless since the 2000s additional
organisms have been increasingly reported: methicillin-resistant⁎ Corresponding author. Tel.: +33 3 80 29 32 60; fax: +33 3 80 29 36 67.
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http://dx.doi.org/10.1016/j.jcf.2012.08.005S. aureus, Stenotrophomonas maltophilia, Burkholderia cepacia
complex and Achromobacter xylosoxidans [2–5]. The impact of
A. xylosoxidans on lung disease is unclear but the recent study by
Hansen suggests that it can cause inflammation in chronically
infected CF patients [6].
A. xylosoxidans is an aerobic, non-fermentative, Gram-
negative rod. It is frequently misidentified as P. aeruginosa,
and therefore its prevalence is likely to be underestimated in
lung colonisation/infection in CF patients [7,8].
The rate of colonisation/infection is very different among the
studies, ranging from 2% in the 2000s [9] to 21% in 2011 [10].by Elsevier B.V. All rights reserved.
Table 1
Characteristics of the patients and isolates. C: chronically colonised patient; CIP: ciprofloxacin; CAZ: ceftazidime; IPM: imipenem; MEM: meropenem.
Patient Age at first
positive culture
PFGE pulsotype
(no. of subtypes)
No. of positive cultures
(no. of strains)
OXA variant Resistance at first positive
culture (year)
Resistance at last positive
culture (year)
P1C 12 AXX42 12(13) 114m CIP (2004) CIP, CAZ, MEM (2010)
P2C 12 AXX42 12(13) 114m CIP(2004) CIP, CAZ, MEM (2010)
P3 8 AXX61 (2) 2(2) 243d None (2001) CIP (2010)
AXX0 1(1) / None (2002) /
P4 9 AXX0 1(1) 243c CIP, CAZ (2010) /
P5C 16 AXX1 (3) 12(18) 243b CIP, CAZ (2003) CAZ (2007)
P6C 4 AXX1 (6) 56(78) 243b None (1997) CIP, CAZ, IPM, MEM (2010)
P7 18 AXX53 (2) 5(6) 114c None (2007) CIP (2008)
AXX0 1(1) / None (2007) /
AXX0 1(1) / None (2008) /
AXX0 1(1) / None (2010) /
P8C 18 AXX2 (6) 79(86) 114h CIP (1997) CIP, CAZ, MEM (2010)
P9C 16 AXX62 (3) 5(9) 114e None (2009) CIP, CAZ (2010)
P10 7 AXX65 2(2) 114i CIP (2010) CIP (2010)
P11 25 AXX56 4(4) 114 l CIP (2006) CIP, MEM (2010)
P12 8 AXX46 (3) 9(11) 114g CIP, CAZ,IPM (2005) CIP (2010)
P13C 22 AXX50 17(23) 114a CIP (2006) CIP (2010)
AXX55 4(4) 114f CIP (2008) CIP(2008)
P14 34 AXX0 1(1) 114k CIP (2005) /
AXX47 2(2) / CIP (2005) CIP (2005)
P15 13 AXX43 15(18) 114i None (2004) CIP (2006)
P16 17 AXX57 2(2) 114f None (2008) None (2008)
P17 25 AXX59 (2) 8(9) 243d CIP, CAZ (2009) CIP, CAZ (2010)
AXX63 2(2) 114c CIP (2010) CIP (2010)
P18 16 AXX58 (2) 3(3) 114c None (2007) CIP (2008)
P19C 25 AXX3 (8) 80(134) 114h CIP (1995) CIP, CAZ, MEM (2010)
P20 4 AXX43 1(1) 114i CIP, CAZ (2005) /
P21 3 AXX0 1(1) 114a CIP (2010) /
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prevalence of A. xylosoxidans in the CF population [11,12].
The reservoir of the isolates remains unknown. Most patients
harbour their own strain but cross-contamination has also been
described in some centres [10,13,14]. As previously described,
this species is naturally resistant to cefalotin, cefoxitin, cefotaxime,
aztreonam, and aminoglycosides [15,16]. OXA-114 has been
described as a constitutive beta-lactamase in A. xylosoxidans [17].
Subsequently it has been proposed as an identification tool of this
species by Turton who reported several variants of this enzyme
[18].
A good knowledge of local epidemiological data is necessary to
detect cross-contamination or common-source outbreak. It will be
also a help to progress in the understanding of the phenomenon
leading to the worldwide emergence of this pathogen.
This study is a retrospective analysis of the 120 CF patients
affiliated with our centre in 2010, from their first visit to
December 2010. Among them, 111 visited the centre in 2010
and sputum analysis was obtained for 108 of them.
The aim of this study was
i. To perform the genotypic analysis of all isolates of
A. xylosoxidans recovered from the patients from their first
visit in our centre until the 31st of December 2010 by
Pulsed Field Gel Electrophoresis (PFGE) and to compare
the performance of the typing provided by the Diversilab®
technology to that of PFGE.ii. To evaluate the evolution of the antimicrobial suscepti-
bility of the isolates.
iii. To detect and sequence the blaOXA-114 gene.
2. Materials and methods
2.1. Patients
One hundred and twenty patients receive care in the CF Centre
of the Paediatric Department of Dijon's Hospital: the CRCM
(Centre de Ressources et de Compétences pour la Mucoviscidose).
Most patients attend regularly the centre: every three months or
every month for the youngest, 111 in 2010. All bacteriological
analyses are performed in our Laboratory of Bacteriology. In this
study, we will use the term “colonisation” referring to a positive
culture and not “infection” because we did not include any clinical
data concerning the lung function of the patients. Patients were
considered chronically colonised according to the criteria defined
by Pereira: “when at least three positive cultures in 1 year were
obtained, with a minimum 1-month interval between them, for at
least 2 years” [10]. The definition was applied retrospectively to
each of the colonised patients listed in Table 1.
2.2. Processing of sputum samples
The sputum are pre-treated (V/V) with Digest'EUR
(Eurobio) for fluidification and then mixed vigorously to obtain
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Cetrimide agar and Burkholderia cepacia selective agar (not
diluted), Trypticase Soy agar with 5% sheep blood (aerobic and
anaerobic conditions), Chocolate agar and Drigalski agar (after
dilution).
2.3. Identification
A. xylosoxidans colonies are lactose-negative, oxidase-
positive and non-pigmented on Muller–Hinton agar.
Isolates were identified as A. xylosoxidans by conventional
methods including API 20NE (bioMérieux, Marcy l'Etoile,
France) and were submitted to further identification when these
conventional methods failed or in case of unusual phenotype of
resistance. For this purpose we used Matrix-Assisted Laser-
Desorption/Ionization Time-of-Flight mass spectrometry (MALDI
Biotyper, Bruker) and sequencing of the whole rrs gene with
primers P8: (5′-AGAGTTTGATCCTGGCTCAG-3′) and P1525:
(5′-AAGGAGGTGATCCAGCCGCA-3′) [19].
2.4. Detection and sequencing of blaOXA-114-like genes
The blaOXA-114 gene was sequenced in at least one isolate from
each PFGE pulsotype recovered more than twice and in four
isolates recovered only once (total of 41 strains). We used either
the primer pair OXA-114A: (5′-ACGCCTGAACCCTTTTAT
CC-3′) and OXA-114B: (5′-ATCGACAGGCCGGGCAGT-3′)
[17] or AXXAF: (5′-TGTCCAAGACCGGCAACTC-3′) and
AXXAR (5′-ACCAGCAGGATCGACAGTC-3′) designed from
the whole genome shotgun sequence of A. xylosoxidans isolate
AXX-A (Genbank accession number AFRQ01000000). Positive
PCR products were purified with a Millipore centrifugal filter unit
(AmiconMicrocon PCR kit, Millipore). Double strand sequencing
was then performed using BigDye v1.1 Terminator chemistry and
a 3130XL Genetic Analyzer (Applied Biosystems).
2.5. Reference strains
Reference strains A. xylosoxidansCIP 7132T, CIP 102062, CIP
102236, CIP 101902 and strain AXX-A were used as positive
controls andAchromobacter ruhlandiiCIP 7726T,Achromobacter
denitrificans CIP 7715T, Achromobacter spanius CIP 108199T,
Achromobacter piechaudii CIP 6075T, Bordetella petrii CIP
107267T, Bordetella bronchiseptica CIP 55110T, Alcaligenes
faecalis CIP 6080 T were used for negative controls for PCR
blaOXA-114.
2.6. Susceptibility testing
Susceptibility testing of the isolates was performed by the disk
diffusion method according to recommendations of the French
Society for Microbiology (http://www.sfm.asso.fr/). Minimal
inhibitory concentrations (MICs) of meropenem and imipenem
were determined by E-test (bioMérieux, Marcy l'Etoile, France).
For each patient, we compared the susceptibility of the first
isolate with the susceptibility of the last one.2.7. Pulsed Field Gel Electrophoresis (PFGE)
All the strains identified as A. xylosoxidans in the respiratory
samples of the CF patients since their first visit were submitted
to genotypic analysis by PFGE as already described [20].
Isolates were analysed using restriction enzyme XbaI. Electro-
phoresis was carried out for 20 h at 5.4 V/cm, with pulse-times
ranging from 5 s to 35 s using the CHEF-DR® II system
(Bio-Rad). Restriction patterns were interpreted according to
Tenover's criteria [21], and the isolates have been classified
into different pulsotypes. The pulsotypes have been numbered
(e.g. AXX1 for A. xylosoxidans pulsotype 1). Pulsotypes that
differed by two or three fragments were considered to be subtypes
(e.g. AXX1A, AXX1B, AXX1C…) according to Tenover's
criteria [21]. “AXX0” was attributed to pulsotypes recovered
only once and different from all those already identified to date in
our hospital. Therefore all “AXX0” pulsotypes are distinct and
unique.
2.8. Automated repetitive-PCR DNA fingerprinting
A total of 42 strains isolated from 19 patients were analysed
by repetitive sequence-based PCR (rep-PCR; DiversiLab®) for
comparison with PFGE results.
Total bacterial DNA was extracted with the UltraClean™
Microbial DNA Isolation Kit (MO Bio Laboratories, Carlsbad,
CA, USA) following the manufacturer's instructions. The yield
of extracted total DNA was estimated by NanoDrop® ND-1000
(LabTech.) and adjusted to approximately 25 to 50 ng/μL.
Rep-PCR was performed using the Diversilab® Bacterial Kit
(bioMérieux SA, Marcy l'Etoile, France) and AmpliTaq®
DNA Polymerase with GeneAmp® 10× PCR Buffer (Applied
Biosystems, Foster City, CA ) in a final volume of 25 μL
following the manufacturer's instructions. Rep-PCR profiles
were obtained using Diversilab® LabChip Devices (bioMérieux
SA, Marcy l'Etoile, France) and an Agilent 2100 BioAnalyzer
(Agilent Technologies, Santa Clara, CA, USA). Fingerprinting
profiles were compared by the DiversiLab® (version 3.4)
software using the Pearson correlation coefficient. The isolates
were considered to belong to the same pattern when similarity
was above 95% and profiles showed two or less peak changes.
The isolates were classified into different patterns if similarity
was less than 95% or if profiles showed more than two peak
changes. One number was attributed to each pattern.
3. Results
3.1. Patients and isolates
The results are summarised in Table 1.
A total of 447 isolates identified as A. xylosoxidans in the
respiratory samples of the CF patients were recovered. Sometimes,
on culture media, different morphotypes of A. xylosoxidans
displaying different antimicrobial susceptibility were encountered.
Therefore the number of isolates (447) is higher than the number of
positive cultures (339). Twenty-one out of the 120 patients
affiliated with the centre in 2010 had at least one positive culture
Table 2
Comparision of genotyping by Diversilab® technology with PFGE on strains
isolated from 19 patients.
Patient Date of isolation PFGE pulsotype Diversilab pattern
P1 16/05/2007 AXX42 1
10/11/2010 AXX42 2
P2 25/07/2007 AXX42 1
26/10/2010 AXX42 2
P3 11/07/2001 AXX61A 3
26/01/2010 AXX61B 4
P4 17/03/2010 AXX0 5
P5 23/06/2004 AXX1A 6
P6 17/06/2005 AXX1A 6
23/07/2009 AXX1C 7
06/12/2010 AXX1C 8
P7 21/07/2007 AXX53A 9
27/09/2007 AXX53A 9
15/05/2008 AXX53B 10
P8 11/09/2007 AXX2C 11
22/11/2007 AXX2A 11
04/06/2009 AXX2C 12
07/09/2010 AXX2A 12
P9 03/02/2010 AXX62A 13
27/10/2010 AXX62A 13
P10 14/09/2010 AXX65 14
07/12/2010 AXX65 14
P11 06/03/2008 AXX56 15
25/02/2010 AXX56 16
06/05/2010 AXX56 16
P12 01/07/2009 AXX46A 17
03/03/2010 AXX46B 17
P13 15/11/2007 AXX50A 18
17/07/2008 AXX55 19
10/11/2010 AXX50A 18
P14 04/08/2005 AXX0 20
P15 04/04/2005 AXX43 21
30/08/2006 AXX43 21
P16 25/05/2008 AXX57 22
P17 13/01/2010 AXX63 23
13/01/2010 AXX59A 24
18/03/2010 AXX59A 24
18/03/2010 AXX63 23
P19 09/01/2002 AXX3B 25
30/11/2006 AXX3A 25
29/04/2010 AXX3B 26
P21 27/01/2010 AXX0 27
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from 15 patients out of the 108 from whom sputum analysis was
performed (13.9%).
The number of isolates per patient ranged from one (3 patients:
P4, P20 and P21) to 134 over 15 years (P19). Eight patients were
chronically colonised according to the criteria described above
(6.7%).
A. xylosoxidans was mostly associated with other pathogens
in the specimens, except for 2 patients (P13 and P19) from
whom A. xylosoxidans was isolated alone in 9 and 11 sputum
samples respectively. Associated pathogenic bacteria weremostly
S. aureus, H. influenzae, Enterobacteriaceae, P. aeruginosa,
or S. maltophilia (data not shown).
Median age at first positive culture was 16 years (range:
3–34).
3.2. Genotyping analysis by PFGE
The 447 isolates recovered from the 21 patients have been
submitted to genotypic analysis by PFGE. The 447 isolates
belonged to 25 distinct genotypes. We have detected three
cases of cross-contamination. It was an intra-familial one for
patients P1 and P2 as well as for patients P5 and P6. The
patients P15 and P20 who shared the genotype AXX43 were
unrelated. Strains isolated successively from the same patient
had the same genotype. The strains are consistent over time,
even over very long periods: 13 years for P6 and P8 to 15 years
for P19. Five patients harboured isolates of different genotypes:
either once sporadically (patients P3, P7 and P14), or for a
longer period (patients P13 and P17). Among them it is
noteworthy that the newly acquired strain never replaced the
initial one.
3.3. Genotyping by Diversilab® technology
Genotyping of strains of A. xylosoxidans by rep-PCR was
performed for 42 strains isolated from 19 patients (1 to 4
isolates per patient) (Table 2).
The 42 strains were classified into 27 genotypes by
Diversilab® technology and only into 19 genotypes by PFGE.
All strains that belonged to different PFGE genotypes also
belonged to different genotypes as determined by Diversilab®.
Nevertheless strains that belonged to the same PFGE genotype
were classified into different genotypes by Diversilab® for
8 patients (i.e. patients P1, P2, P3, P7, P8, P11, P13 and P19).
Indeed, minor differences in the profiles determined by PFGE led
to the classification of the isolates in the same pattern whereas
minor variations in the profiles determined by rep-PCR led to the
classification of the isolates in different patterns.
3.4. Antibiotic susceptibility
The 447 isolates of A. xylosoxidans included in the study
displayed the innate resistance of the species to aztreonam,
cefalotin, cefoxitin, cefotaxime, kanamycin, amikacin, tobramycin,
gentamicin, netilmicin, nalidixic acid and ofloxacin. We report
here for each patient the susceptibility of the first isolate incomparison with the susceptibility of the last one to the
following molecules: ceftazidime, piperacillin/tazobactam,
imipenem, meropenem and ciprofloxacin (year of isolation
indicated in Table 1). At first positive culture, the isolate was
susceptible to these 5 antibiotics for 7 patients, resistant to
ceftazidime for 5 patients, resistant to imipenem for 1 patient
and resistant to ciprofloxacin for 16 patients. At last positive
culture, isolates resistant to ceftazidime have been recovered
from 7 patients. The evolution of carbapenem resistance is
important mainly among strains recovered from chronically
colonised patients: in 2010, 6 patients harboured strains with
decreased susceptibility to meropenem (Table 3). For 3
isolates, MIC of imipenem was much lower than MIC of
meropenem. Piperacillin/tazobactam was the most active
molecule: no resistant strain has been detected in 2010.
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The entire blaOXA-114like gene from 41 strains (20 different
PFGE patterns) was sequenced.
Analysis of the sequences revealed polymorphisms. We have
detected five variants (bla OXA-114 a, c, e, f, g) already described
[17,18] and five new variants (bla OXA-114 h, i, k, l, m). (Genbank
accession numbers JX206446; JX206447; JX206449; JX206450;
JX206451). Moreover we have found a new oxacillinase differing
from OXA-114a by 34 amino acid substitutions (88% identity).
This enzyme was assigned the number OXA-243 (http://www.
lahey.org/Studies/). A total of four variants of this enzyme were
characterised in four isolates as well as in the reference strain
AXX-A (bla OXA-243 a, b, c, d). Genbank accession numbers
JX206453; JX206454; JX206455; JX206456). All isolates that
belonged to the same genotype harboured the same bla OXA gene.
4. Discussion
This is the first epidemiological study about A. xylosoxidans
in a French CF centre. Among the 120 affiliated patients, 21
had at least one positive culture since their first visit. In 2010,
positive(s) culture(s) were obtained for 13.9% of the 108
patients for whom sputum analysis was performed. This
percentage is much higher than the 4.4% reported in the French
global data in 2010 (http://www.vaincrelamuco.org/e_upload/
pdf/rapport_registre_2010.pdf). This difference might be due to
misidentification in some centres as already reported [8,22].
According to our experience, many isolates of A. xylosoxidans
share common properties with non-pigmented isolates of
P. aeruginosa: aerobic, oxidase positive, growth at 41 °C but not
at 4 °C, growth on cetrimide medium. The difficulty of identifica-
tion is enhanced in case of co-culture of both species.
Such a high prevalence has already been reported in some
other European centres: 17.6% (among 300 patients) in Italy
[23] or 17.9% in a Belgian CF centre (among 140 patients)
[22]. Nevertheless the median age at first positive culture was
16 years in our centre which is younger compared to the
Belgian centre (median: 20 years). Eight of our patients (6.7%)
were chronically colonised with A. xylosoxidans. It is a long-
term colonisation, these patients being still colonised in 2011
and 2012 (except patient P5, who did not visit the centre since
2007). This rate is somewhat higher than in the Belgian centre
(5.6%). Using the same criteria as De Baets (at least 3 positive
cultures over at least nine months) the number of chronically
colonised patients in our centre would be of 10% instead ofTable 3
MICs (mg/L) of imipenem and meropenem of isolates recovered in 2010 with
decreased susceptibility to imipenem and/or meropenem. (E-test method).
Patient Imipenem Meropenem
P1 3 4
P2 16 3
P6 4 4
P8 3 N32
P11 4 N32
P19 2 N326.7%. To date, the highest rate of chronically colonised patients
has been reported in a Brazilian centre: 12.8% [10].
The genotypic analysis by PFGE results proved that patients
harboured their own strain. Thanks to the analysis of the strains
isolated successively from the patients we have demonstrated
that this long-term colonisation lasted over 15 years for one
patient. We did not observe strain displacement. As PFGE
analysis is time consuming we compared this method with the
Diversilab® technology. This is the first study of this typing
method for A. xylosoxidans strains. In all cases, isolates that
were classified as unrelated by PFGE were also classified as
different by Diversilab ®. Nevertheless, some isolates belong-
ing to the same PFGE pattern were classified as different by
Diversilab®. Such discrepancies were already described for other
bacterial species such as Pseudomonas aeruginosa [24]. It
happened when isolates were recovered with more than 8 months
interval. It seems therefore that Diversilab® is more sensitive than
PFGE to minor variations of the strains over time. We conclude
that PFGE remains the reference method for the survey of
long-term colonisation. We propose the Diversilab® as a useful
and rapid typing tool to compare isolates recovered simulta-
neously when an outbreak is suspected or for the comparison of
clinical isolates with environmental isolates as already suggested
for other pathogens [25].
The cross-contamination between patients was very uncommon
in our centre except in 2 cystic fibrosis families. A cross-
contamination occurred also between two unrelated patients, one
colonised and one non- colonised patient visiting the centre the
same day. Nevertheless, it is important to note that the non-
colonised patient never happened to have A. xylosoxidans again in
his subsequent expectorations.
Some patients were colonised with a second strain, genotyp-
ically distinct. This co-colonisation was sporadic and lasted for a
short time (mostly less than one year).
This diversity of genotypes suggests that the majority of
A. xylosoxidans isolates fromCF patients probably originate from
domestic environmental sources. A study of environmental
samples might be a help to identify the potential source(s).
Acquired resistance to antibiotics was frequent. The first
isolates recovered from our patients were mostly resistant to
ciprofloxacin and the mechanism leading to this resistance has to
be explored. Acquired resistance to ceftazidime and carbapenems
was high among patients attending our centre, and concerned
mainly chronically colonised patients.
Repeated administration of antibiotics to treat infections due
to common pathogens, especially P. aeruginosa, might explain
this selection of resistant A. xylosoxidans.
It is also important to note that for the first time we report an
unusual phenotype in the strains resistant to carbapenems, some
of them being much more resistant to meropenem than to
imipenem.We recently described the efflux systemAxyXY-oprZ
in A. xylosoxidans which can extrude meropenem (submitted
manuscript). The production level of this system will be explored
in the clinical isolates to assess its potential contribution to
meropenem resistance. Our results are not in accord with Jacquier
who recently reported that meropenem displays an interesting
antimicrobial activity against A. xylosoxidans as compared with
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the activity of meropenem is comparable to that of imipenem
on 53 isolates [23]. The recommendations for the treatment of
A. xylosoxidans infection in CF patients are to use intravenous
combination of antibiotics including either imipenem or
meropenem [27]. Therefore more data are needed to propose
the most active carbapenem.
OXA-114 has been described as constitutive in A. xylosoxidans
[17]. We have detected a wide diversity of blaOXA-114 genes as
reported elsewhere [18] as well as five new variants of this enzyme.
Nevertheless the primers proposed by Turton did not allow the
detection of blaOXA-114 in all our isolates. This highlights the limits
of the method. More interestingly we also detected the new
oxacillinase OXA-243 with 3 variants. The identification of the
isolates harbouring blaOXA-243 was confirmed by sequencing
house-keeping genes (data not shown). This method proved to be a
very discriminant tool for identification of A. xylosoxidans. A
similar method has been published very recently [28]. We have
detected the different variants of OXA-114 and OXA-243 among
strains harbouring various phenotypes of antimicrobial resistance.
Therefore these enzymes do not account for acquired resistance to
ceftazidime or carbapenems. The diversity of oxacillinases
produced by clinical strains might only reflect the diversity of
A. xylosoxidans natural reservoirs.5. Conclusion
This study reports for the first time the survey of colonisation of
21 patients by A. xylosoxidans since it was first isolated. The
prevalence of A. xylosoxidans is high in our CF centre. Till nowwe
observed very rare cross-contamination between patients. There is
a wide diversity of the isolates and the length of colonisation is
sometimes very long. Our main concern is the acquired
antimicrobial resistance of the isolates, especially in chronically
colonised patients. These first French data including a very large
number of isolates should be compared with those of other CF
centres from France.References
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